MEDINET Co., Ltd. (2370.T)
JPY 37.0
(0.0%)
JPY 37.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 590.2 Million JPY | 4.25% |
| 2022 | 566.13 Million JPY | 19.2% |
| 2021 | 474.94 Million JPY | 7.21% |
| 2020 | 442.98 Million JPY | -10.28% |
| 2019 | 493.72 Million JPY | -20.89% |
| 2018 | 624.05 Million JPY | -20.56% |
| 2017 | 785.59 Million JPY | -54.21% |
| 2016 | 1.71 Billion JPY | -0.5% |
| 2015 | 1.72 Billion JPY | 17.44% |
| 2014 | 1.46 Billion JPY | -21.61% |
| 2013 | 1.87 Billion JPY | -21.7% |
| 2012 | 2.39 Billion JPY | -5.77% |
| 2011 | 2.53 Billion JPY | 33.3% |
| 2010 | 1.9 Billion JPY | 232.95% |
| 2009 | 571.94 Million JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 517.25 Million JPY | -2.96% |
| 2024 Q1 | 548.62 Million JPY | -7.04% |
| 2024 Q2 | 533.01 Million JPY | -2.84% |
| 2023 Q2 | 528.81 Million JPY | 17.95% |
| 2023 Q3 | 563.96 Million JPY | 6.65% |
| 2023 Q4 | 590.2 Million JPY | 4.65% |
| 2023 Q1 | 448.35 Million JPY | -20.81% |
| 2023 FY | 590.2 Million JPY | 4.25% |
| 2022 Q1 | 553.34 Million JPY | 16.51% |
| 2022 FY | 566.13 Million JPY | 19.2% |
| 2022 Q4 | 566.13 Million JPY | 5.03% |
| 2022 Q3 | 539.01 Million JPY | -18.88% |
| 2022 Q2 | 664.43 Million JPY | 20.07% |
| 2021 Q1 | 512.17 Million JPY | 15.62% |
| 2021 FY | 474.94 Million JPY | 7.21% |
| 2021 Q4 | 474.94 Million JPY | -4.32% |
| 2021 Q3 | 496.36 Million JPY | 3.07% |
| 2021 Q2 | 481.56 Million JPY | -5.98% |
| 2020 Q4 | 442.98 Million JPY | 11.79% |
| 2020 FY | 442.98 Million JPY | -10.28% |
| 2020 Q2 | 447.55 Million JPY | 1.03% |
| 2020 Q3 | 396.25 Million JPY | -11.46% |
| 2020 Q1 | 443 Million JPY | -10.27% |
| 2019 Q1 | 552.62 Million JPY | -11.45% |
| 2019 Q4 | 493.72 Million JPY | -11.88% |
| 2019 Q3 | 560.27 Million JPY | 0.64% |
| 2019 Q2 | 556.7 Million JPY | 0.74% |
| 2019 FY | 493.72 Million JPY | -20.89% |
| 2018 Q4 | 624.05 Million JPY | -8.17% |
| 2018 Q3 | 679.59 Million JPY | -7.29% |
| 2018 Q2 | 733.05 Million JPY | -58.57% |
| 2018 Q1 | 1.76 Billion JPY | 125.24% |
| 2018 FY | 624.05 Million JPY | -20.56% |
| 2017 Q4 | 785.59 Million JPY | -57.0% |
| 2017 Q2 | 1.74 Billion JPY | 0.13% |
| 2017 Q3 | 1.82 Billion JPY | 4.7% |
| 2017 FY | 785.59 Million JPY | -54.21% |
| 2017 Q1 | 1.74 Billion JPY | 1.58% |
| 2016 Q1 | 2.18 Billion JPY | 26.62% |
| 2016 Q2 | 2.17 Billion JPY | -0.29% |
| 2016 Q3 | 1.67 Billion JPY | -23.12% |
| 2016 Q4 | 1.71 Billion JPY | 2.51% |
| 2016 FY | 1.71 Billion JPY | -0.5% |
| 2015 FY | 1.72 Billion JPY | 17.44% |
| 2015 Q2 | 1.61 Billion JPY | 11.92% |
| 2015 Q1 | 1.44 Billion JPY | -1.47% |
| 2015 Q4 | 1.72 Billion JPY | 2.69% |
| 2015 Q3 | 1.67 Billion JPY | 3.71% |
| 2014 Q3 | 1.37 Billion JPY | -0.7% |
| 2014 Q2 | 1.38 Billion JPY | -13.79% |
| 2014 Q1 | 1.6 Billion JPY | -14.09% |
| 2014 FY | 1.46 Billion JPY | -21.61% |
| 2014 Q4 | 1.46 Billion JPY | 6.59% |
| 2013 Q2 | 1.47 Billion JPY | -40.01% |
| 2013 Q3 | 2.06 Billion JPY | 40.19% |
| 2013 Q4 | 1.87 Billion JPY | -9.18% |
| 2013 FY | 1.87 Billion JPY | -21.7% |
| 2013 Q1 | 2.45 Billion JPY | 2.5% |
| 2012 Q3 | 2.38 Billion JPY | -0.77% |
| 2012 Q4 | 2.39 Billion JPY | 0.19% |
| 2012 FY | 2.39 Billion JPY | -5.77% |
| 2012 Q1 | 2.34 Billion JPY | -7.68% |
| 2012 Q2 | 2.4 Billion JPY | 2.67% |
| 2011 FY | 2.53 Billion JPY | 33.3% |
| 2011 Q1 | 2.23 Billion JPY | 17.48% |
| 2011 Q2 | 2.44 Billion JPY | 9.24% |
| 2011 Q3 | 2.33 Billion JPY | -4.5% |
| 2011 Q4 | 2.53 Billion JPY | 8.75% |
| 2010 Q1 | 422.04 Million JPY | -26.21% |
| 2010 Q2 | 417.14 Million JPY | -1.16% |
| 2010 FY | 1.9 Billion JPY | 232.95% |
| 2010 Q4 | 1.9 Billion JPY | -3.61% |
| 2010 Q3 | 1.97 Billion JPY | 373.62% |
| 2009 FY | 571.94 Million JPY | 0.0% |
| 2009 Q2 | 339.98 Million JPY | 10.06% |
| 2009 Q4 | 571.94 Million JPY | 0.0% |
| 2009 Q1 | 308.9 Million JPY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 3.24 Billion JPY | 81.823% |
| PRISM BioLab Co.,LTD | 63.41 Million JPY | -830.76% |
| GNI Group Ltd. | 26.34 Billion JPY | 97.759% |
| Linical Co., Ltd. | 10.3 Billion JPY | 94.273% |
| Trans Genic Inc. | 3.81 Billion JPY | 84.519% |
| Soiken Holdings Inc. | 697.02 Million JPY | 15.325% |
| Cytori Cell Research Institute, Inc. | 3.02 Billion JPY | 80.462% |
| AnGes, Inc. | 2.78 Billion JPY | 78.841% |
| OncoTherapy Science, Inc. | 513.6 Million JPY | -14.914% |
| Nxera Pharma Co., Ltd. | 90.38 Billion JPY | 99.347% |
| Immuno-Biological Laboratories Co., Ltd. | 353.27 Million JPY | -67.068% |
| NanoCarrier Co., Ltd. | 1.64 Billion JPY | 64.228% |
| Carna Biosciences, Inc. | 472.35 Million JPY | -24.949% |
| CanBas Co., Ltd. | 91.98 Million JPY | -541.61% |
| D. Western Therapeutics Institute, Inc. | 1.09 Billion JPY | 46.031% |
| RaQualia Pharma Inc. | 809.83 Million JPY | 27.12% |
| Chiome Bioscience Inc. | 593.73 Million JPY | 0.594% |
| Kidswell Bio Corporation | 4.25 Billion JPY | 86.126% |
| PeptiDream Inc. | 29.11 Billion JPY | 97.973% |
| Oncolys BioPharma Inc. | 566.5 Million JPY | -4.184% |
| Ribomic Inc. | 155.8 Million JPY | -278.8% |
| SanBio Company Limited | 2.25 Billion JPY | 73.826% |
| Healios K.K. | 11.28 Billion JPY | 94.77% |
| BrightPath Biotherapeutics Co., Ltd. | 251.26 Million JPY | -134.889% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 369 Million JPY | -59.947% |
| Delta-Fly Pharma, Inc. | 241.49 Million JPY | -144.394% |
| StemRIM | 187 Million JPY | -215.617% |
| CellSource Co., Ltd. | 677.73 Million JPY | 12.916% |
| FunPep Company Limited | 189.32 Million JPY | -211.743% |
| Kringle Pharma, Inc. | 596.95 Million JPY | 1.131% |
| Stella Pharma Corporation | 1.44 Billion JPY | 59.116% |
| TMS Co., Ltd. | 97.68 Million JPY | -504.166% |
| Noile-Immune Biotech Inc. | 91.49 Million JPY | -545.074% |
| Cuorips Inc. | 200.96 Million JPY | -193.691% |
| K Pharma,Inc. | 209.13 Million JPY | -182.213% |
| Takara Bio Inc. | 11.42 Billion JPY | 94.832% |
| ReproCELL Incorporated | 741.03 Million JPY | 20.354% |
| PhoenixBio Co., Ltd. | 917.71 Million JPY | 35.688% |
| StemCell Institute Inc. | 3.85 Billion JPY | 84.672% |
| Japan Tissue Engineering Co., Ltd. | 908.43 Million JPY | 35.03% |
| CellSeed Inc. | 301.04 Million JPY | -96.05% |